Skip to content

Effect of Guduchyadi Taila Uttar Basti and Rasnadi Ksheerpaka Orally in Vataja Yonivyapad

A Comparative Clinical Study on the Therapeutic Effect of Guduchyadi Taila Uttar Basti and Rasnadi Ksheerpaka Orally in Vataja Yonivyapad - No

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/03/063422
Enrollment
60
Registered
2024-03-01
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N946- Dysmenorrhea, unspecified

Interventions

None listed

Sponsors

Department of Prasuti Tantra
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Married women of 20-40 years of age. 2. Patient having complaint of pain during menses along with one or more than one symptomatology from the following at least two previous consecutive cycle- (a)Pain in abdomen during menses. (b)Decrease duration of menstrual blood [duration of blood loss is 2 days or less than 2 day]. (c)Decrease amount of menstrual blood [quantity of menstrual is less than 20ml]. (d)With thin, dry, frothy characteristic of menstrual blood. (e)Sensory symptoms numbness, roughness or stiffness in genital region. (f)Associated symptoms nausea, vomiting, bodyache, headache.

Exclusion criteria

Exclusion criteria: 1.Women below 20 years and above 45 years of age. 2.Unmarried or Pregnant women 3.Women with systemic diseases like TB, DM, Jaundice, Bronchial Asthma, Cardiovascular diseases, Renal diseases or Acute gastrointestinal conditions like Appendicitis, Cholecystitis, Hepatitis, pancreatitis, gastric ulcer. 4.Women having complaint of Menorrhagia. 5.Patients having STD, Carcinoma of Cervix, Large cervical polyp, Acute active genital infections, bartholin abscess, Large bartholin cyst, large vaginal cyst, large, polypoidal fibroid, Uterine prolapse (2or 3degree), extensive ectropion. 6.Skin disease in perineal region like eczema, herpes. 7.Patient is on chemotherapy / radio therapy for any malignant condition of any organ. 8.Women having any psychological disorders. 9.Women having lactose intolerance.

Design outcomes

Primary

MeasureTime frame
Assessment will be done on the following parameters: Dysmenorrhea (WaLIDD Score) Pelvic pain (VAS Scale) Amount of menstrual blood loss Duration of blood loss Colour of menstrual blood Fatigue / lethargy Characteristic of menstrual blood thin/dry/frothy in nature Sensory changes numbness, stiffness, roughness in genital region. Associated symptoms nausea, vomiting, bodyache headache.Timepoint: Two month with medication and one month with out medication

Secondary

MeasureTime frame
Reduce pelvic pain and improvement in sensory changes numbness stiffness roughness of genital regionTimepoint: two follow up with medication and one follow up without medication total 90 days duration

Countries

India

Contacts

Public ContactProf Deepa Mishra

Institute of Medical Sciences BHU

mamtaanu09@gmail.com9616941751

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026